Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Abstract:

BACKGROUND:Several anthropometric measures have been found to be associated with the risk of breast cancer. Current weight, body mass index, and adult weight gain appear to be predictors of postmenopausal breast cancer. These factors have been associated with a reduced risk of premenopausal breast cancer. We asked whether there is an association between changes in body weight and the risk of breast cancer in women who carry a mutation in either breast cancer susceptibility gene, BRCA1 or BRCA2. METHODS:A matched case-control study was conducted in 1,073 pairs of women carrying a deleterious mutation in either BRCA1 (n = 797 pairs) or BRCA2 (n = 276 pairs). Women diagnosed with breast cancer were matched to control subjects by year of birth, mutation, country of residence, and history of ovarian cancer. Information about weight was derived from a questionnaire routinely administered to women who were carriers of a mutation in either gene. Conditional logistic regression was used to estimate the association between weight gain or loss and the risk of breast cancer, stratified by age at diagnosis or menopausal status. RESULTS:A loss of at least 10 pounds in the period from age 18 to 30 years was associated with a decreased risk of breast cancer between age 30 and 49 (odds ratio (OR) = 0.47; 95% confidence interval (CI) 0.28-0.79); weight gain during the same interval did not influence the overall risk. Among the subgroup of BRCA1 mutation carriers who had at least two children, weight gain of more than 10 pounds between age 18 and 30 was associated with an increased risk of breast cancer diagnosed between age 30 and 40 (OR = 1.44, 95% CI 1.01-2.04). Change in body weight later in life (at age 30 to 40) did not influence the risk of either premenopausal or postmenopausal breast cancer. CONCLUSION:The results from this study suggest that weight loss in early adult life (age 18 to 30) protects against early-onset BRCA-associated breast cancers. Weight gain should also be avoided, particularly among BRCA1 mutation carriers who elect to have at least two pregnancies.

journal_name

Breast Cancer Res

authors

Kotsopoulos J,Olopado OI,Ghadirian P,Lubinski J,Lynch HT,Isaacs C,Weber B,Kim-Sing C,Ainsworth P,Foulkes WD,Eisen A,Sun P,Narod SA

doi

10.1186/bcr1293

keywords:

subject

Has Abstract

pub_date

2005-01-01 00:00:00

pages

R833-43

issue

5

eissn

1465-5411

issn

1465-542X

pii

bcr1293

journal_volume

7

pub_type

杂志文章
  • Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?

    abstract::Zoledronic acid (ZA) is an imidazole-containing bisphosphonate that has been extensively studied as an osteoclast inhibitor. ZA decreases bone turnover and has been effective in limiting osteolysis in metastatic cancers, including breast cancer. Recent clinical trials that demonstrated enhancement of disease-free surv...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr3223

    authors: Steinman RA,Brufsky AM,Oesterreich S

    更新日期:2012-09-21 00:00:00

  • An investigation of soy intake and mammographic characteristics in Hawaii.

    abstract::This cross-sectional investigation in Hawaii explored the relation between soy foods and mammographic characteristics using two food frequency questionnaires and a computer-assisted density assessment method. Japanese and Chinese women reported significantly greater soy food intake than Caucasian women. Whereas soy in...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr285

    authors: Maskarinec G,Meng L

    更新日期:2001-01-01 00:00:00

  • Psychiatric disorders and cardiovascular diseases during the diagnostic workup of potential breast cancer: a population-based cohort study in Skåne, Sweden.

    abstract:BACKGROUND:An increasing number of women are evaluated for potential breast cancer and may experience mental distress during evaluation. We aim to assess the risks of psychiatric disorders and cardiovascular diseases during the diagnostic workup of potential breast cancer. METHODS:All women with a new diagnosis of uns...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-019-1232-y

    authors: Shen Q,Jöud A,Schelin MEC,Sjölander A,Cao Y,Sparén P,Fall K,Czene K,Valdimarsdóttir U,Fang F

    更新日期:2019-12-10 00:00:00

  • Expression genomics in breast cancer research: microarrays at the crossroads of biology and medicine.

    abstract::Genome-wide expression microarray studies have revealed that the biological and clinical heterogeneity of breast cancer can be partly explained by information embedded within a complex but ordered transcriptional architecture. Comprising this architecture are gene expression networks, or signatures, reflecting biochem...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr1662

    authors: Miller LD,Liu ET

    更新日期:2007-01-01 00:00:00

  • Diffuse optical spectroscopic imaging reveals distinct early breast tumor hemodynamic responses to metronomic and maximum tolerated dose regimens.

    abstract:BACKGROUND:Breast cancer patients with early-stage disease are increasingly administered neoadjuvant chemotherapy (NAC) to downstage their tumors prior to surgery. In this setting, approximately 31% of patients fail to respond to therapy. This demonstrates the need for techniques capable of providing personalized feedb...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-020-01262-1

    authors: Tank A,Peterson HM,Pera V,Tabassum S,Leproux A,O'Sullivan T,Jones E,Cabral H,Ko N,Mehta RS,Tromberg BJ,Roblyer D

    更新日期:2020-03-13 00:00:00

  • Finding the needle in the haystack: why high-throughput screening is good for your health.

    abstract::High-throughput screening is an essential component of the toolbox of modern technologies that improve speed and efficiency in contemporary cancer drug development. This is particularly important as we seek to exploit, for maximum therapeutic benefit, the large number of new molecular targets emerging from the Human G...

    journal_title:Breast cancer research : BCR

    pub_type: 社论

    doi:10.1186/bcr440

    authors: Aherne GW,McDonald E,Workman P

    更新日期:2002-01-01 00:00:00

  • An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers.

    abstract:INTRODUCTION:Individuals carrying pathogenic mutations in the BRCA1 and BRCA2 genes have a high lifetime risk of breast cancer. BRCA1 and BRCA2 are involved in DNA double-strand break repair, DNA alterations that can be caused by exposure to reactive oxygen species, a main source of which are mitochondria. Mitochondria...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0567-2

    authors: Blein S,Bardel C,Danjean V,McGuffog L,Healey S,Barrowdale D,Lee A,Dennis J,Kuchenbaecker KB,Soucy P,Terry MB,Chung WK,Goldgar DE,Buys SS,Breast Cancer Family Registry.,Janavicius R,Tihomirova L,Tung N,Dorfling CM,va

    更新日期:2015-04-25 00:00:00

  • Selective gene-expression profiling of migratory tumor cells in vivo predicts clinical outcome in breast cancer patients.

    abstract:INTRODUCTION:Metastasis of breast cancer is the main cause of death in patients. Previous genome-wide studies have identified gene-expression patterns correlated with cancer patient outcome. However, these were derived mostly from whole tissue without respect to cell heterogeneity. In reality, only a small subpopulatio...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3344

    authors: Patsialou A,Wang Y,Lin J,Whitney K,Goswami S,Kenny PA,Condeelis JS

    更新日期:2012-10-31 00:00:00

  • Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study.

    abstract:BACKGROUND:The global observational BREAKOUT study investigated germline BRCA mutation (gBRCAm) prevalence in a population of patients with human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). METHODS:Eligible patients had initiated first-line cytotoxic chemotherapy for HER2-negativ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,多中心研究

    doi:10.1186/s13058-020-01349-9

    authors: O'Shaughnessy J,Brezden-Masley C,Cazzaniga M,Dalvi T,Walker G,Bennett J,Ohsumi S

    更新日期:2020-10-27 00:00:00

  • Chemically induced DNA hypomethylation in breast carcinoma cells detected by the amplification of intermethylated sites.

    abstract:INTRODUCTION:Compromised patterns of gene expression result in genomic instability, altered patterns of gene expression and tumour formation. Specifically, aberrant DNA hypermethylation in gene promoter regions leads to gene silencing, whereas global hypomethylation events can result in chromosomal instability and onco...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr799

    authors: Sadikovic B,Haines TR,Butcher DT,Rodenhiser DI

    更新日期:2004-01-01 00:00:00

  • FAK activates AKT-mTOR signaling to promote the growth and progression of MMTV-Wnt1-driven basal-like mammary tumors.

    abstract:BACKGROUND:Breast cancer is a heterogeneous disease. Hence, stratification of patients based on the subtype of breast cancer is key to its successful treatment. Among all the breast cancer subtypes, basal-like breast cancer is the most aggressive subtype with limited treatment options. Interestingly, we found focal adh...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-020-01298-3

    authors: Paul R,Luo M,Mo X,Lu J,Yeo SK,Guan JL

    更新日期:2020-06-03 00:00:00

  • Identification of signaling pathways in early mammary gland development by mouse genetics.

    abstract::The mammary gland develops as an appendage of the ectoderm. The prenatal stage of mammary development is hormone independent and is regulated by sequential and reciprocal signaling between the epithelium and the mesenchyme. A number of recent studies using human and mouse genetics, in particular targeted gene deletion...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr776

    authors: Robinson GW

    更新日期:2004-01-01 00:00:00

  • Breast cancer prognosis by combinatorial analysis of gene expression data.

    abstract:INTRODUCTION:The potential of applying data analysis tools to microarray data for diagnosis and prognosis is illustrated on the recent breast cancer dataset of van 't Veer and coworkers. We re-examine that dataset using the novel technique of logical analysis of data (LAD), with the double objective of discovering patt...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1512

    authors: Alexe G,Alexe S,Axelrod DE,Bonates TO,Lozina II,Reiss M,Hammer PL

    更新日期:2006-01-01 00:00:00

  • The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome.

    abstract:INTRODUCTION:Estrogens play a pivotal role in the initiation and progression of breast cancer. The genes that mediate these processes are not fully defined, but potentially include the known mammary oncogene MYC. Characterization of estrogen-target genes may help to elucidate further the mechanisms of estrogen-induced ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1985

    authors: Butt AJ,Sergio CM,Inman CK,Anderson LR,McNeil CM,Russell AJ,Nousch M,Preiss T,Biankin AV,Sutherland RL,Musgrove EA

    更新日期:2008-01-01 00:00:00

  • Profiling gene promoter occupancy of Sox2 in two phenotypically distinct breast cancer cell subsets using chromatin immunoprecipitation and genome-wide promoter microarrays.

    abstract:INTRODUCTION:Aberrant expression of the embryonic stem cell marker Sox2 has been reported in breast cancer (BC). We previously identified two phenotypically distinct BC cell subsets separated based on their differential response to a Sox2 transcription activity reporter, namely the reporter-unresponsive (RU) and the mo...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-014-0470-2

    authors: Jung K,Wang P,Gupta N,Gopal K,Wu F,Ye X,Alshareef A,Bigras G,McMullen TP,Abdulkarim BS,Lai R

    更新日期:2014-11-08 00:00:00

  • New generation breast cancer cell lines developed from patient-derived xenografts.

    abstract:BACKGROUND:Breast cancer is a highly heterogeneous disease characterized by multiple histologic and molecular subtypes. While a myriad of breast cancer cell lines have been developed over the past 60 years, estrogen receptor alpha (ER)+ disease and some mutations associated with this subtype remain underrepresented. He...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-020-01300-y

    authors: Finlay-Schultz J,Jacobsen BM,Riley D,Paul KV,Turner S,Ferreira-Gonzalez A,Harrell JC,Kabos P,Sartorius CA

    更新日期:2020-06-23 00:00:00

  • Inducible transgenics. New lessons on events governing the induction and commitment in mammary tumorigenesis.

    abstract::Breast cancer arises from multiple genetic events that together contribute to the established, irreversible malignant phenotype. The development of inducible tissue-specific transgenics has allowed a careful dissection of the events required for induction and subsequent maintenance of tumorigenesis. Mammary gland targ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr297

    authors: Hulit J,Di Vizio D,Pestell RG

    更新日期:2001-01-01 00:00:00

  • Gene expression in murine mammary epithelial stem cell-like cells shows similarities to human breast cancer gene expression.

    abstract:INTRODUCTION:Mammary stem cells are bipotential and suggested to be the origin of breast cancer development, but are elusive and vaguely characterized. Breast tumors can be divided into subgroups, each one requiring specific treatment. To determine a possible association between mammary stem cells and breast cancer, a ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2256

    authors: Williams C,Helguero L,Edvardsson K,Haldosén LA,Gustafsson JA

    更新日期:2009-01-01 00:00:00

  • Potential for the embryonic morphogen Nodal as a prognostic and predictive biomarker in breast cancer.

    abstract:INTRODUCTION:The re-emergence of the tumour growth factor-beta (TGF-beta)-related embryonic morphogen Nodal has recently been reported in several different human cancers. In this study, we examined the expression of Nodal in a series of benign and malignant human breast tissues to determine the clinical significance of...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3185

    authors: Strizzi L,Hardy KM,Margaryan NV,Hillman DW,Seftor EA,Chen B,Geiger XJ,Thompson EA,Lingle WL,Andorfer CA,Perez EA,Hendrix MJ

    更新日期:2012-05-11 00:00:00

  • Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion.

    abstract:BACKGROUND:We previously performed a case-control genome-wide association study in women treated with selective estrogen receptor modulators (SERMs) for breast cancer prevention and identified single nucleotide polymorphisms (SNPs) in ZNF423 as potential biomarkers for response to SERM therapy. The ZNF423rs9940645 SNP,...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-017-0890-x

    authors: Qin S,Ingle JN,Liu M,Yu J,Wickerham DL,Kubo M,Weinshilboum RM,Wang L

    更新日期:2017-08-18 00:00:00

  • Chromogenic in situ hybridization (CISH): a novel alternative in screening archival breast cancer tissue samples for HER-2/neu status.

    abstract:BACKGROUND:Chromogenic in situ hybridization (CISH) is emerging as a practical, cost-effective, and valid alternative to fluorescent in situ hybridization in testing for gene alteration, especially in centers primarily working with immunohistochemistry (IHC). METHODS:We assessed Her-2/neu alteration using CISH on form...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr915

    authors: Madrid MA,Lo RW

    更新日期:2004-01-01 00:00:00

  • Variation in breast cancer risk associated with factors related to pregnancies according to truncating mutation location, in the French National BRCA1 and BRCA2 mutations carrier cohort (GENEPSO).

    abstract:INTRODUCTION:Mutations in BRCA1 and BRCA2 confer a high risk of breast cancer (BC), but the magnitude of this risk seems to vary according to the study and various factors. Although controversial, there are data to support the hypothesis of allelic risk heterogeneity. METHODS:We assessed variation in BC risk according...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr3218

    authors: Lecarpentier J,Noguès C,Mouret-Fourme E,Gauthier-Villars M,Lasset C,Fricker JP,Caron O,Stoppa-Lyonnet D,Berthet P,Faivre L,Bonadona V,Buecher B,Coupier I,Gladieff L,Gesta P,Eisinger F,Frénay M,Luporsi E,Lortholary A,

    更新日期:2012-07-03 00:00:00

  • Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study.

    abstract:INTRODUCTION:Radiation exposure at a young age is one of the strongest risk factors for breast cancer. Germline mutations in genes involved in the DNA-damage repair pathway (DDRP) may render women more susceptible to radiation-induced breast cancer. METHODS:We evaluated the contribution of germline mutations in the DD...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1668

    authors: Broeks A,Braaf LM,Huseinovic A,Nooijen A,Urbanus J,Hogervorst FB,Schmidt MK,Klijn JG,Russell NS,Van Leeuwen FE,Van 't Veer LJ

    更新日期:2007-01-01 00:00:00

  • Prognostic stromal gene signatures in breast cancer.

    abstract:INTRODUCTION:Global gene expression analysis of tumor samples has been a valuable tool to subgroup tumors and has the potential to be of prognostic and predictive value. However, tumors are heterogeneous, and homogenates will consist of several different cell types. This study was designed to obtain more refined expres...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/s13058-015-0530-2

    authors: Winslow S,Leandersson K,Edsjö A,Larsson C

    更新日期:2015-02-21 00:00:00

  • Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers.

    abstract:INTRODUCTION:The majority of breast cancers that occur in BRCA1 mutation carriers (BRCA1 carriers) are estrogen receptor-negative (ER-). Therefore, it has been suggested that ER negativity is intrinsic to BRCA1 cancers and reflects the cell of origin of these tumors. However, approximately 20% of breast cancers that de...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2776

    authors: Tung N,Miron A,Schnitt SJ,Gautam S,Fetten K,Kaplan J,Yassin Y,Buraimoh A,Kim JY,Szász AM,Tian R,Wang ZC,Collins LC,Brock J,Krag K,Legare RD,Sgroi D,Ryan PD,Silver DP,Garber JE,Richardson AL

    更新日期:2010-01-01 00:00:00

  • Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3.

    abstract:INTRODUCTION:Metastasis is a common event and the main cause of death in cancer patients. Lymphangiogenesis refers to the formation of new lymphatic vessels and is thought to be involved in the development of metastasis. Sunitinib is a multi-kinase inhibitor that blocks receptor tyrosine kinase activity, including that...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr2903

    authors: Kodera Y,Katanasaka Y,Kitamura Y,Tsuda H,Nishio K,Tamura T,Koizumi F

    更新日期:2011-06-21 00:00:00

  • Breast cancer in Marin County.

    abstract::Two articles previously published in Breast Cancer Research illustrate the high rates of breast cancer in Marin County, a wealthy, urban county immediately northwest of the city of San Francisco. I herein comment on these articles, and on the political/psychological/scientific dilemma presented by regions with high ca...

    journal_title:Breast cancer research : BCR

    pub_type: 评论,杂志文章,评审

    doi:10.1186/bcr633

    authors: Whittemore AS

    更新日期:2003-01-01 00:00:00

  • Breast cancer stem cells: implications for therapy of breast cancer.

    abstract::The concept of cancer stem cells responsible for tumour origin, maintenance, and resistance to treatment has gained prominence in the field of breast cancer research. The therapeutic targeting of these cells has the potential to eliminate residual disease and may become an important component of a multimodality treatm...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr2111

    authors: Morrison BJ,Schmidt CW,Lakhani SR,Reynolds BA,Lopez JA

    更新日期:2008-01-01 00:00:00

  • Estrogen regulation of mammary gland development and breast cancer: amphiregulin takes center stage.

    abstract::Estrogen-mediated proliferation is fundamental to normal mammary gland development. Recent studies have demonstrated that amphiregulin is a critical paracrine regulator of estrogen action during ductal morphogenesis. These studies implicate a critical role for amphiregulin in mammary stem cell differentiation as well ...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章,评审

    doi:10.1186/bcr1740

    authors: LaMarca HL,Rosen JM

    更新日期:2007-01-01 00:00:00

  • Additive growth inhibitory effects of ibandronate and antiestrogens in estrogen receptor-positive breast cancer cell lines.

    abstract:INTRODUCTION:Bisphosphonates are inhibitors of osteoclast-mediated tumor-stimulated osteolysis, and they have become standard therapy for the management of bone metastases from breast cancer. These drugs can also directly induce growth inhibition and apoptosis of osteotropic cancer cells, including estrogen receptor-po...

    journal_title:Breast cancer research : BCR

    pub_type: 杂志文章

    doi:10.1186/bcr1363

    authors: Journe F,Chaboteaux C,Magne N,Duvillier H,Laurent G,Body JJ

    更新日期:2006-01-01 00:00:00